Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Challenges in drug target discovery in bipolar disorder.

Alsaif M, Haenisch F, Guest PC, Rahmoune H, Bahn S.

Expert Opin Ther Targets. 2013 May;17(5):565-77. doi: 10.1517/14728222.2013.771169. Epub 2013 Feb 18. Review.

PMID:
23419165
2.

Novel routes to bipolar disorder drug discovery.

Hoertel N, de Maricourt P, Gorwood P.

Expert Opin Drug Discov. 2013 Aug;8(8):907-18. doi: 10.1517/17460441.2013.804057. Epub 2013 May 27. Review.

PMID:
23706065
3.

Epigenetic approaches for bipolar disorder drug discovery.

Peedicayil J.

Expert Opin Drug Discov. 2014 Aug;9(8):917-30. doi: 10.1517/17460441.2014.922537. Epub 2014 May 29. Review.

PMID:
24875048
4.

Drugs under early investigation for the treatment of bipolar disorder.

Konstantakopoulos G, Dimitrakopoulos S, Michalopoulou PG.

Expert Opin Investig Drugs. 2015 Apr;24(4):477-90. doi: 10.1517/13543784.2015.1019061. Epub 2015 Feb 23. Review.

PMID:
25704484
5.

Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder.

Dodd S, Fernandes BS, Dean OM.

Curr Neuropharmacol. 2015;13(5):656-62. Review.

6.

Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?

Fornaro M, Aguglia E, Dell'Osso L, Perugi G.

Expert Opin Pharmacother. 2011 Dec;12(18):2817-31. doi: 10.1517/14656566.2011.632366. Review.

PMID:
22098226
7.

Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers.

Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK.

Mol Psychiatry. 2004 Aug;9(8):734-55. Review.

PMID:
15136794
8.

Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.

Gould TD, Zarate CA, Manji HK.

J Clin Psychiatry. 2004 Jan;65(1):10-21. Review.

PMID:
14744163
9.

Modeling complex genetic and environmental influences on comorbid bipolar disorder with tobacco use disorder.

McEachin RC, Saccone NL, Saccone SF, Kleyman-Smith YD, Kar T, Kare RK, Ade AS, Sartor MA, Cavalcoli JD, McInnis MG.

BMC Med Genet. 2010 Jan 26;11:14. doi: 10.1186/1471-2350-11-14.

10.

Therapeutic use of omega-3 fatty acids in bipolar disorder.

Balanzá-Martínez V, Fries GR, Colpo GD, Silveira PP, Portella AK, Tabarés-Seisdedos R, Kapczinski F.

Expert Rev Neurother. 2011 Jul;11(7):1029-47. doi: 10.1586/ern.11.42. Review.

PMID:
21721919
11.

[Neuropatological and neurochemical abnormalities in bipolar disorder].

Frey BN, Fonseca MM, Machado-Vieira R, Soares JC, Kapczinski F.

Rev Bras Psiquiatr. 2004 Sep;26(3):180-8. Epub 2004 Nov 17. Review. Portuguese.

12.

Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD).

Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Calabrese J, Kupfer D, Rosenbaum JF.

Biol Psychiatry. 2003 Jun 1;53(11):1028-42. Review.

PMID:
12788248
13.

Neurobiology of bipolar disorder.

Newberg AR, Catapano LA, Zarate CA, Manji HK.

Expert Rev Neurother. 2008 Jan;8(1):93-110. Review.

PMID:
18088203
14.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
15.

The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?

Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS.

Neurotoxicology. 2009 Jul;30(4):497-521. doi: 10.1016/j.neuro.2009.03.004. Epub 2009 Mar 24. Review.

PMID:
19477018
16.

Gsk3 Signalling and Redox Status in Bipolar Disorder: Evidence from Lithium Efficacy.

Luca A, Calandra C, Luca M.

Oxid Med Cell Longev. 2016;2016:3030547. doi: 10.1155/2016/3030547. Epub 2016 Aug 18. Review.

17.

Glycogen synthase kinase 3: an emerging therapeutic target.

Eldar-Finkelman H.

Trends Mol Med. 2002 Mar;8(3):126-32. Review.

PMID:
11879773
18.

The multicellular tumor spheroid model for high-throughput cancer drug discovery.

LaBarbera DV, Reid BG, Yoo BH.

Expert Opin Drug Discov. 2012 Sep;7(9):819-30. doi: 10.1517/17460441.2012.708334. Epub 2012 Jul 12. Review.

PMID:
22788761
19.

Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development.

Nierenberg AA, Kansky C, Brennan BP, Shelton RC, Perlis R, Iosifescu DV.

Aust N Z J Psychiatry. 2013 Jan;47(1):26-42. doi: 10.1177/0004867412449303. Epub 2012 Jun 18. Review.

PMID:
22711881
20.

Review of the use of topiramate for treatment of bipolar disorders.

Suppes T.

J Clin Psychopharmacol. 2002 Dec;22(6):599-609. Review.

PMID:
12454560

Supplemental Content

Support Center